Agios Pharmaceuticals Inc (AGIO)
31.44
-0.23
(-0.73%)
USD |
NASDAQ |
Apr 26, 13:44
Agios Pharmaceuticals Cash from Financing (Quarterly): 0.847M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.847M |
| September 30, 2023 | 1.882M |
| June 30, 2023 | 0.237M |
| March 31, 2023 | 2.467M |
| December 31, 2022 | 0.022M |
| September 30, 2022 | 1.187M |
| June 30, 2022 | -0.067M |
| March 31, 2022 | 1.208M |
| December 31, 2021 | -18.59M |
| September 30, 2021 | -250.98M |
| June 30, 2021 | -503.46M |
| March 31, 2021 | 7.261M |
| December 31, 2020 | 0.582M |
| September 30, 2020 | 3.448M |
| June 30, 2020 | 252.10M |
| March 31, 2020 | 5.385M |
| December 31, 2019 | 277.61M |
| September 30, 2019 | 3.337M |
| June 30, 2019 | 3.808M |
| March 31, 2019 | 4.86M |
| December 31, 2018 | 1.016M |
| September 30, 2018 | 7.223M |
| June 30, 2018 | 9.508M |
| March 31, 2018 | 528.28M |
| Date | Value |
|---|---|
| December 31, 2017 | 2.589M |
| September 30, 2017 | 5.322M |
| June 30, 2017 | 273.15M |
| March 31, 2017 | 4.046M |
| December 31, 2016 | 3.993M |
| September 30, 2016 | 163.23M |
| June 30, 2016 | 1.449M |
| March 31, 2016 | 1.108M |
| December 31, 2015 | 1.287M |
| September 30, 2015 | 2.173M |
| June 30, 2015 | 1.091M |
| March 31, 2015 | 1.822M |
| December 31, 2014 | 239.06M |
| September 30, 2014 | 0.367M |
| June 30, 2014 | 95.15M |
| March 31, 2014 | 0.582M |
| December 31, 2013 | -0.424M |
| September 30, 2013 | 124.23M |
| June 30, 2013 | 0.047M |
| March 31, 2013 | 0.025M |
| December 31, 2012 | 0.054M |
| September 30, 2012 | 0.034M |
| June 30, 2012 | 0.016M |
| March 31, 2012 | 0.038M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-503.46M
Minimum
Jun 2021
277.61M
Maximum
Dec 2019
-11.14M
Average
1.208M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 39.23M |
| Blueprint Medicines Corp | 15.53M |
| Corcept Therapeutics Inc | 0.766M |
| Ionis Pharmaceuticals Inc | 40.72M |
| Madrigal Pharmaceuticals Inc | 479.92M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -72.49M |
| Cash from Investing (Quarterly) | 95.51M |
| Free Cash Flow | -314.56M |
| Free Cash Flow Per Share (Quarterly) | -1.300 |
| Free Cash Flow to Equity (Quarterly) | -72.72M |
| Free Cash Flow Yield | -17.98% |